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Vitiligo presents with striking depigmented cutaneous le-
sions and a histologic loss of functional melanocytes and
melanin. Three major theories exist to explain this loss
of melanocytes. First, the destruction of melanocytes is
thought to be mediated by external factors including chang-
es in neurological mediators that affect melanocyte function
and/or survival. Second, melanocytes are altered by intrin-
sic factors including toxic metabolites within the melanin
biosynthesis pathway (Lerner, 1971) that affect structure
and/or function. Third, an autoimmune mechanism leads to
melanocyte destruction.
Autoimmune Vitiligo
The evidence for autoimmunity is based on multiple clinical
and research findings in humans and animals (Ongenae
et al, 2003). Vitiligo is associated with coexisting autoim-
mune disorders and organ-specific antibodies. In addition,
routine non-surgical repigmenting treatment utilizes im-
mune-modulators including topical corticosteroids and
inhibitors of the calcineurin pathway (tacrolimus). These in-
directly support the argument for an immune etiology of
disease. Myeloid cells are also implicated in that monocytes
from patients with active disease produce increased pro-
inflammatory cytokines and CD68þ macrophages are
abundant in the dermis. Large patient groups have also
shown aberrations in T cell and natural killer cell profiles in
vitiligo patients supporting a role for cell-mediated immu-
nity. T cell infiltrates are invariably seen at the site of de-
pigmentation in patients with active disease. Furthermore,
high frequencies of cytotoxic T lymphocytes specific for
melanocytic antigens are detected in vitiligo patients, im-
plicating a direct melanocyte specific T cell attack.
Autoimmunity and Tolerance
The hallmark of organ-specific autoimmune diseases is the
disruption of the immune system’s normal homeostatic bal-
ance leading to tissue destruction. In healthy people the
immune system maintains the ability to recognize 25 million
different antigens (Arstila et al, 1999) and provides surveil-
lance against a multitude of foreign pathogens without any
pathologic response to self-antigens. There are two known
mechanisms by which we become tolerant or unresponsive
to self-antigens. First, T and B cells are deleted in the thy-
mus and bone marrow to remove those cells that pose the
greatest threat. Despite this mechanism (known as central
deletion or central tolerance), some precursor self-reactive
cells will escape deletion, mature, and populate peripheral
tissues but still do not attack self. The second mechanism
of tolerance, a phenomenon known as peripheral tolerance,
involves the regulation of self-reactive cells by multiple reg-
ulatory pathways. A central hypothesis in vitiligo research
is that immune tolerance to self-melanocyte antigens is
broken.
In this issue of the Journal of Investigative Dermatology,
Steitz et al demonstrate two requirements to break tolerance
to a MHC class I-restricted peptide derived from a
melanocyte-derived self-antigen, murine tyrosinase-related
protein 2 (TYRP2) (Tu¨ting et al, 2004). The two requirements
are (1) CD4 T cell help and (2) local inflammation at the site
of self-antigen endogenous expression. Although previously
the authors showed the repeated local intradermal immuni-
zation led to the local depigmentation of melanocytes, now
the authors show that systemic intraperitoneal immunization
must be accompanied by a subsequent local gene gun in-
jection of plasmid DNA-coated gold particles or application
of the contact allergen 2,4-dinitrofluorobenzene (DNFB). The
data provide evidence that both CD4þ T cell help induced
by the systemic immunization as well as local inflammation
are required to break MHC class-I-restricted Tcell tolerance.
The exact nature of the local inflammation required to
break the tolerance remains, however, to be examined, and
could be immunologically specific or non-specific in nature.
One may extrapolate that the unmethylated CpG (CG-rich
sequences, also referred to as immunostimulatory sequenc-
es, ISS) contained within the double stranded plasmid DNA
produced by bacteria may stimulate the innate arm of the
immune system by signaling through the pattern recognition
receptor, Toll-like receptor 9 (TLR9), to provide a ‘‘danger
signal’’ (Matzinger, 1994). TLR9 ligands have been shown to
stimulate the production of interferon (IFN)-g, IFN-a, IFN-b,
and interleukins (IL) 12 and 18, all of which foster Th1 re-
sponses and enhance cell-mediated immunity (Roman et al,
1997). The requirement for TLR9 could also be tested by
repeating these experiments in TLR9- or myeloid differen-
tiation factor 88 (MyD88)-deficient mice. MyD88 is a down-
stream signaling intermediary important for the effects of
TLR9 ligation. An alternative possibility is that the inflam-
mation is nonspecific, caused by the mechanical trauma
induced by the introduction of gold particles into skin. It
would therefore be interesting to know whether gold par-
ticles without DNA would also trigger depigmentation.
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Minor trauma alone is well known to cause new skin le-
sions in vitiligo patients. This is known as the Koebner phe-
nomenon (Sweet, 1978), first described in psoriasis, which
refers to the appearance of clinical lesions in ‘‘uninvolved
skin’’ as a result of mechanical trauma. In psoriasis, this
uninvolved skin is not, however, normal, but expresses a
predominance of CD4 over CD8 T cells in the epidermis
compared with skin from normal donors. It is hypothesized
that these immune alterations in the presence of the trau-
ma-induced alterations lead to clinical disease. Trauma in
Koebner-prone psoriatic patients stimulates the accumula-
tion of CD4þ T cells at the site of injury (Paukkonen et al,
1992). To our knowledge similar studies have not been per-
formed in vitiligo patients.
There is much to learn about vitiligo from studies of mel-
anoma vaccination in patients with metastatic disease un-
dergoing immunotherapy. One vaccination strategy has
been to enhance T cell activation during immunization by
blocking cytotoxic T lymphocyte-associated antigen 4
(CTLA-4), a critical receptor that downregulates T cell ac-
tivation. Prior treatment with CTLA-4 before with the mel-
anocyte-specific protein gp100 resulted in vitiligo in 2/14
patients (Phan et al, 2003). In other studies (Houghton,
1994), immunizations using xenogeneic orthologs to facil-
itate T cell recognition or heteroclitic epitopes with in-
creased affinity to the MHC also results in vitiligo. These
data indicate that normal regulatory pathways prevent the
emergence of immune reactivity to self-antigens expressed
by melanocytes, yet immune dysregulation can lead to
vitiligo.
Breaking Tolerance—New Concepts
Recent immunologic insights into mechanisms of immune
tolerance impact our understanding and potential treatment
of vitiligo. It is now well known that T cells produce distinct
patterns of cytokines that are cross-regulatory in nature;
Th1 cytokine are involved in cell-mediated immunity and
Th2 cytokines in humoral responses. These cytokine pat-
terns influence the outcome of microbial infection in skin
(Yamamura et al, 1991) and contribute to the pathogenesis
of many inflammatory skin disorders. The skewing of cyto-
kine responses from one pattern to another is termed im-
mune deviation. Much experimental and clinical work is
underway in the attempt to deviate the immune response to
downregulate a destructive immune response. The goal of
this therapy is to increase T helper cells that secrete a Th2
cytokine profile (IL-4, IL-5, IL-10, IL-13). This has been
successfully demonstrated in experimental autoimmune
encephalomyelitis (EAE), the animal model for multiple scle-
rosis, where an antigen-specific Th1 response is pathogenic
and a Th2 response is protective (Young et al, 2000). Both
helper and cytotoxic T cells from progressing margins gen-
erate predominantly type 1 cytokines, namely, IFN-g and
TNF-a (Le Poole et al, 2004), suggesting vitiligo is a Th1-
mediated disease and perhaps immunization to skew the
immune response to a Th2 phenotype may prevent further
progression.
An exciting new area of immunologic interest has been
the identification of immune-regulatory cells (Tregs) and
their role in autoimmune disease (Sakaguchi, 2004). Deple-
tion or functional alteration of naturally occurring CD4þ
Tregs, the majority of which express CD25, leads to the
development of autoimmune disease in otherwise normal
animals. Tregs cells are a functionally distinct and mature
subpopulation of T cells. They possess a repertoire of an-
tigen specificities as broad as that of naı¨ve T cells, and are
capable of recognizing both self- and non-self-antigens,
thus enabling them to control various immune responses.
Comparison of peripheral blood from patients with vitiligo
versus healthy controls has revealed the increased expres-
sion of the activation-associated surface antigen CD25
(Mahmoud et al, 2002). The increased CD25 expression in
vitiligo patients has been interpreted to reflect increased
antigen-mediated activation, but it might also reflect an in-
crease in Tregs. In an animal model of melanoma immuno-
therapy, depletion of all CD4þ T cells including Tregs
resulted in enhanced B16 tumor rejection suggesting a role
for Tregs in maintaining tolerance to melanocyte self-anti-
gens (Nagai et al, 2000). Further studies are required to
determine whether the dysregulation of Tregs is one of the
factors that can break tolerance to melanocyte self-anti-
gens and contribute to the pathogenesis of vitiligo.
By understanding the mechanisms that can break toler-
ance, it is possible to design rational strategies to restore
tolerance in autoimmune disease. This could be achieved
by one or a combination of different approaches (Steinman,
2004). One is the induction of anergy, whereby the patho-
genic T cell is rendered unresponsive to self-antigen. An-
other strategy is to delete autoreactive T cells by inducing
apoptosis, using a mechanism termed activation-induced
cell death. A third attractive approach is by induction of
Tregs specific for autoantigens targeted by pathogenic T
cells. The ideal therapy would simultaneously delete path-
ogenic T cells and induce Tregs. Our ability to manipulate
immune-regulatory pathways holds great promise for de-
veloping new treatments for vitiligo.
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